Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback